Document is current
Any future updates will be listed below
-
Authors
Golkaram, Mahdi
Kuo, Fengshen
Gupta, Sounak
Carlo, Maria I.
Salmans, Michael L.
Vijayaraghavan, Raakhee
Tang, Cerise
Makarov, Vlad
Rappold, Phillip
Blum, Kyle A.
Zhao, Chen
Mehio, Rami
Zhang, Shile
Godsey, Jim
Pawlowski, Traci
DiNatale, Renzo G.
Morris, Luc G. T.
Durack, Jeremy
Russo, Paul
Kotecha, Ritesh R.
Coleman, Jonathan
Chen, Ying-Bei
Reuter, Victor E.
Motzer, Robert J.
Voss, Martin H.
Liu, Li
Reznik, Ed
Chan, Timothy A.
Hakimi, A. Ari
- License Information
-
More Information
Article History
Received: 28 June 2022
Accepted: 29 November 2022
First Online: 19 December 2022
Declarations
:
: All patients involved in this study provided informed consent to participate. Informed consent and institutional review board approval were acquired at Memorial Sloan Kettering Cancer Center (MSK) (protocol number 16–195). This research conformed to the Declaration of Helsinki.
: Consent was obtained from all participants to publish supporting data including Additional file InternalRef removed: Tables S1-S6.
: M.G., R.V., M.L.S., J.G., T.P., R.M., C.Z., S.Z., and L.L. are current employees and shareholders of Illumina Inc. T.A.C. and L.G.T.M. are inventors on a patent held by Memorial Sloan Kettering related to the use of TMB in cancer immunotherapy. MSK has licensed the use of TMB for the identification of patients that benefit from immune checkpoint therapy to PGDx. L.G.T.M. reports laboratory research funding from AstraZeneca. T.A.C. is a co-founder of Gritstone Oncology and holds equity. T.A.C. holds equity in An2H. T.A.C. acknowledges grant funding from Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H, and Eisai. T.A.C. has served as an advisor for Bristol Myers Squibb, Illumina, Eisai, and An2H. R.J.M. reports consulting fees from Aveo, Calithera, Eisai, Eli Lilly, EMD Serono, Genentech, Merck, Novartis AG, Pfizer, and Roche, and contracted research to employer MSKCC for Bristol Myers Squibb, Eisai, Exelixis, Genentech, Merck, Pfizer, and Roche. A.A.H. is on the advisory board for Merck. M.H. receives commercial research grants from Bristol Myers Squibb, Pfizer, and Genentech/Roche, honoraria from Novartis, Bristol Myers Squibb, travel/accommodation from Astra Zeneca, Eisai, Novartis, and Takeda, and is a consultant/advisory board member for Alexion Pharmaceuticals, Aveo, Calithera Biosciences, Corvus Pharmaceuticals, Exelixis, Eisai, GlaxoSmithKline, Merck, Natera; Onquality Pharmaceuticals; Novartis and Pfizer. The remaining authors declare that they have no competing interests.
